Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Change in Receivables (2023 - 2025)

BioXcel Therapeutics has reported Change in Receivables over the past 3 years, most recently at $233000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at $233000.0 for Q4 2025, up 82.03% from a year ago — trailing twelve months through Dec 2025 was $102000.0 (up 70.0% YoY), and the annual figure for FY2025 was $102000.0, up 70.0%.
  • Change in Receivables for Q4 2025 was $233000.0 at BioXcel Therapeutics, up from -$17000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for BTAI hit a ceiling of $434000.0 in Q2 2024 and a floor of -$809000.0 in Q3 2024.
  • Median Change in Receivables over the past 3 years was $81500.0 (2023), compared with a mean of -$1250.0.
  • Peak annual rise in Change in Receivables hit 777.14% in 2024, while the deepest fall reached 366.12% in 2024.
  • BioXcel Therapeutics' Change in Receivables stood at -$664000.0 in 2023, then soared by 119.28% to $128000.0 in 2024, then soared by 82.03% to $233000.0 in 2025.
  • The last three reported values for Change in Receivables were $233000.0 (Q4 2025), -$17000.0 (Q3 2025), and $17000.0 (Q2 2025) per Business Quant data.